Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter
 

Frances Balkwill

Researcher Frances Balkwill profile image

Developing new treatments for ovarian cancer

Barts & The London School of Medicine
John Vane Science Centre
Charterhouse Square
London
EC1M 6BQ
United Kingdom

Email: f.balkwill@qmul.ac.uk
Tel: 020 7882 3885
Web: Lab website

Professor Frances Balkwill leads the Centre for Cancer and Inflammation at Barts & The London School of Medicine & Dentistry. She is investigating the links between cancer and inflammation, with a particular focus on ovarian cancer. Professor Balkwill aims to use the results from her lab studies to develop new anti-cancer treatments, and her team is involved in several early-phase clinical trials.

Inflammation and cancer

The environment inside and around a tumour contains many cells and molecules that are involved in inflammation, which can help cancer cells grow and survive. It can also encourage tumours to grow new blood vessels to supply oxygen and nutrients to the cancer cells, helping them to spread.

Professor Balkwill's research is looking at how inflammation helps tumours grow. She is investigating the role of two molecules called cytokines that are involved in inflammation. Her previous work has shown that these particular cytokines, TNF-alpha and IL-6, play a key role in inflammation in ovarian cancer and other forms of the disease.

The way in which TNF-alpha and IL-6 promote cancer is not fully understood. Scientists know they are produced by cancer cells during growth and spread but Professor Balkwill aims to clarify exactly how they interact with other molecules in the cancer environment to encourage cancer growth.

Listen to an interview with Professor Balkwill, discussing her research into the immune system and cancer:

Clinical trials

Early-stage clinical trials investigating molecules that block the action of TNF-alpha gave promising initial results. This suggests that TNF-alpha may be a useful treatment target. Ongoing clinical trials in women with ovarian cancer are also studying the effect of drugs that block the action of IL-6.

Understanding how inflammation is linked with ovarian cancer will help Professor Balkwill identify who could benefit from this type of treatment. Her research will also establish which treatments could be successfully combined with drugs that block cytokines such as TNF-alpha and IL-6.

Professor Balkwill is also a well-respected science communicator, and has contributed to Queen Mary, University of London's new education centre, the Centre of the Cell.

Visit MyProjects to watch a video about Professor Balkwill's work and to donate directly to her research.

The aim of the programme of research funded by Cancer Research UK is to define the mechanisms of action of the inflammatory cytokine TNF-alpha in promotion and progression of epithelial malignancies. This aim is important for understanding of epithelial-stromal interactions …

Other research projects by Frances Balkwill

Biological Sciences Committee (BSC) Programme Grants
Funding period: 01 October 2008 to 30 September 2013

Publications


Ten Common Genetic Variants Associated with Colorectal Cancer Risk Are Not Associated with Survival after Diagnosis

Clin Cancer Res.2010;16 :3754-3759

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53

Br J Cancer.2010;103 :186-195